Olympic 800m medallist Nijel Amos suspended for doping ahead of worlds
Sample contained drug which can modify metabolism but considered too dangerous for human use

Nijel Amos, an Olympic silver medallist in the men's 800 meters, has been suspended ahead of the world championships after testing positive for a rare banned substance.
The Athletics Integrity Unit said Tuesday that the 28-year-old Amos gave a sample on June 4 which was found to contain GW1516, an experimental drug which can modify the body's metabolism but has been considered too dangerous for human use.
Amos had been set to race the 800 heats of the world championships in Eugene, Oregon, on July 20. He won silver at the 2012 Olympics, becoming the first-ever medallist for Botswana.
"The athlete was notified of the adverse analytical finding and his mandatory provisional suspension this afternoon in Eugene," the AIU said.
GW1516 was developed to help build endurance and burn fat but was found to cause cancer during tests on rodents. Anti-doping organizations have warned athletes not to use it on safety grounds.
The drug has previously been found in samples given by professional cyclists and by Olympic race-walker Elena Lashmanova. The Russian served a two-year ban and was later stripped of the 20-kilometre gold medal she won at the 2012 Olympics for another doping offence.
WATCH | Marco Arop is heating up for worlds:
Comments
To encourage thoughtful and respectful conversations, first and last names will appear with each submission to CBC/Radio-Canada's online communities (except in children and youth-oriented communities). Pseudonyms will no longer be permitted.
By submitting a comment, you accept that CBC has the right to reproduce and publish that comment in whole or in part, in any manner CBC chooses. Please note that CBC does not endorse the opinions expressed in comments. Comments on this story are moderated according to our Submission Guidelines. Comments are welcome while open. We reserve the right to close comments at any time.
Become a CBC Member
Join the conversation Create account
Already have an account?